(ERF) Eurofins Scientific SE - Ratings and Ratios
Exchange: PA • Country: Luxembourg • Currency: EUR • Type: Common Stock • ISIN: FR0014000MR3
ERF: Testing, Analysis, Laboratory, Services, Chemistry, Biology
Eurofins Scientific SE (PA:ERF) stands as a leader in the global analytical testing and laboratory services sector, renowned for its comprehensive suite of services designed to ensure the safety, quality, and regulatory compliance of products across diverse industries. Established in 1987 and headquartered in Luxembourg, the company has carved a niche through its extensive
Additional Sources for ERF Stock
ERF Stock Overview
Market Cap in USD | 9,913m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Biotechnology |
IPO / Inception |
ERF Stock Ratings
Growth 5y | -21.8% |
Fundamental | 31.7% |
Dividend | 9.58% |
Rel. Strength | -5.02 |
Analysts | - |
Fair Price Momentum | 43.30 EUR |
Fair Price DCF | 129.31 EUR |
ERF Dividends
Dividend Yield 12m | 1.00% |
Yield on Cost 5y | 1.26% |
Annual Growth 5y | -7.40% |
Payout Consistency | 76.6% |
ERF Growth Ratios
Growth Correlation 3m | 31.1% |
Growth Correlation 12m | -51.8% |
Growth Correlation 5y | -58.1% |
CAGR 5y | 4.10% |
CAGR/Max DD 5y | 0.06 |
Sharpe Ratio 12m | 0.02 |
Alpha | -26.05 |
Beta | 0.713 |
Volatility | 31.31% |
Current Volume | 439.7k |
Average Volume 20d | 435.8k |
What is the price of ERF stocks?
As of April 02, 2025, the stock is trading at EUR 48.64 with a total of 439,699 shares traded.
Over the past week, the price has changed by -3.53%, over one month by -0.59%, over three months by -0.27% and over the past year by -18.02%.
As of April 02, 2025, the stock is trading at EUR 48.64 with a total of 439,699 shares traded.
Over the past week, the price has changed by -3.53%, over one month by -0.59%, over three months by -0.27% and over the past year by -18.02%.
Is Eurofins Scientific SE a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Eurofins Scientific SE is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 31.74 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ERF as of April 2025 is 43.30. This means that ERF is currently overvalued and has a potential downside of -10.98%.
Neither. Based on ValueRay Fundamental Analyses, Eurofins Scientific SE is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 31.74 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ERF as of April 2025 is 43.30. This means that ERF is currently overvalued and has a potential downside of -10.98%.
Is ERF a buy, sell or hold?
Eurofins Scientific SE has no consensus analysts rating.
Eurofins Scientific SE has no consensus analysts rating.
What are the forecast for ERF stock price target?
According to ValueRays Forecast Model, ERF Eurofins Scientific SE will be worth about 47.3 in April 2026. The stock is currently trading at 48.64. This means that the stock has a potential downside of -2.86%.
According to ValueRays Forecast Model, ERF Eurofins Scientific SE will be worth about 47.3 in April 2026. The stock is currently trading at 48.64. This means that the stock has a potential downside of -2.86%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 58.1 | 19.4% |
Analysts Target Price | - | - |
ValueRay Target Price | 47.3 | -2.9% |